amantadine has been researched along with Chorea Disorders in 21 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "Huntington chorea, like levodopa-induced dyskinesias, may be responsive to amantadine hydrochloride treatment." | 9.10 | A randomized trial of amantadine in Huntington disease. ( Dewey, RB; O'Suilleabhain, P, 2003) |
| "We report an 80-year-old woman with hemichorea probably due to amantadine hydrochloride." | 7.69 | [A case of multiple cerebral infarctions associated with hemichorea induced by amantadine hydrochloride]. ( Morimatsu, M; Negoro, K; Tsuda, N, 1994) |
| "Paraneoplastic chorea is typically a subacute progressive hyperkinetic movement disorder." | 5.51 | Anti-CV2/CRMP5 Paraneoplastic Chorea Effectively Managed with Intravenous Amantadine. ( Ahn, JH; Cho, JW; Ha, J; Kim, JS; Kim, JW; Kim, M; Lee, JH; Na, BS; Youn, J, 2019) |
| "Chorea scores were lower with amantadine (usually 400 mg/d) than placebo, with a median reduction in extremity chorea at rest of 36% (p = 0." | 5.10 | Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. ( Chase, TN; Farmer, C; Gillespie, M; Morris, MJ; Mosby, K; Verhagen Metman, L; Wuu, J, 2002) |
| "Huntington chorea, like levodopa-induced dyskinesias, may be responsive to amantadine hydrochloride treatment." | 5.10 | A randomized trial of amantadine in Huntington disease. ( Dewey, RB; O'Suilleabhain, P, 2003) |
| "If HD chorea requires treatment, clinicians should prescribe tetrabenazine (up to 100 mg/day), amantadine (300-400 mg/day), or riluzole (200 mg/day) (Level B) for varying degrees of expected benefit." | 3.78 | Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. ( Armstrong, MJ; Miyasaki, JM, 2012) |
| "We report an 80-year-old woman with hemichorea probably due to amantadine hydrochloride." | 3.69 | [A case of multiple cerebral infarctions associated with hemichorea induced by amantadine hydrochloride]. ( Morimatsu, M; Negoro, K; Tsuda, N, 1994) |
| "We have studied the urinary excretion of 1,4-methylhistamine (1,4-MeHm), 5-hydroxyindole-3-acetic acid (5-HIAA) and homovanillic acid (HVA) in patients with Parkinson's disease, choreiform movements and essential tremor." | 3.65 | Urinary monoamine metabolite excretion in disorders of movement. Effects of amantadine and levodopa. ( Fleming, AM; Lenman, JA; Reid, A; Turnbull, MJ, 1977) |
| "Cranial CT revealed a chronic subdural hematoma (CSDH) that covered the left parietal lobe." | 2.58 | [Chorea due to chronic subdural hematoma]. ( Kanemaru, K; Murayama, S; Sengoku, R; Shibukawa, M; Shiraishi, T; Takanashi, S, 2018) |
| "Paraneoplastic chorea is typically a subacute progressive hyperkinetic movement disorder." | 1.51 | Anti-CV2/CRMP5 Paraneoplastic Chorea Effectively Managed with Intravenous Amantadine. ( Ahn, JH; Cho, JW; Ha, J; Kim, JS; Kim, JW; Kim, M; Lee, JH; Na, BS; Youn, J, 2019) |
| "Treatment included induction of coma while a native immune response matured; rabies vaccine was not administered." | 1.33 | Survival after treatment of rabies with induction of coma. ( Amlie-Lefond, CM; Chusid, MJ; Ghanayem, NS; Hoffman, GM; Rupprecht, CE; Schwabe, MJ; Tieves, KS; Willoughby, RE, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (42.86) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 5 (23.81) | 29.6817 |
| 2010's | 6 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ha, J | 2 |
| Na, BS | 2 |
| Ahn, JH | 2 |
| Kim, M | 2 |
| Kim, JW | 2 |
| Lee, JH | 2 |
| Cho, JW | 2 |
| Kim, JS | 2 |
| Youn, J | 2 |
| Doher, N | 1 |
| Gupta, HV | 1 |
| Shiraishi, T | 1 |
| Sengoku, R | 1 |
| Takanashi, S | 1 |
| Shibukawa, M | 1 |
| Kanemaru, K | 1 |
| Murayama, S | 1 |
| Park, H | 1 |
| Jeon, BS | 1 |
| Shin, JH | 1 |
| Park, SH | 1 |
| Armstrong, MJ | 1 |
| Miyasaki, JM | 1 |
| Verhagen Metman, L | 1 |
| Morris, MJ | 1 |
| Farmer, C | 1 |
| Gillespie, M | 1 |
| Mosby, K | 1 |
| Wuu, J | 1 |
| Chase, TN | 1 |
| O'Suilleabhain, P | 1 |
| Dewey, RB | 1 |
| Furukawa, Y | 1 |
| Filiano, JJ | 1 |
| Kish, SJ | 1 |
| Willoughby, RE | 1 |
| Tieves, KS | 1 |
| Hoffman, GM | 1 |
| Ghanayem, NS | 1 |
| Amlie-Lefond, CM | 1 |
| Schwabe, MJ | 1 |
| Chusid, MJ | 1 |
| Rupprecht, CE | 1 |
| Bonelli, RM | 1 |
| Hofmann, P | 1 |
| Tsuda, N | 1 |
| Negoro, K | 1 |
| Morimatsu, M | 1 |
| Gray, MW | 1 |
| Herzberg, L | 1 |
| Lerman, JA | 1 |
| Turnbull, MJ | 2 |
| Victoratos, G | 1 |
| Agnoli, A | 1 |
| Ruggieri, S | 1 |
| Casacchia, M | 1 |
| Lenman, JA | 1 |
| Reid, A | 1 |
| Fleming, AM | 1 |
| Mundinger, F | 1 |
| Milios, E | 1 |
| Godwin-Austen, RB | 1 |
| Frears, CC | 1 |
| Bergmann, S | 1 |
| Parkes, JD | 1 |
| Knill-Jones, RP | 1 |
| Schergna, E | 1 |
| Ferro-Milone, F | 1 |
| Parisen-Toldin, P | 1 |
| Borromei, A | 1 |
| Lorizio, A | 1 |
| Ecari, U | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD)[NCT00127114] | Phase 4 | 0 participants (Actual) | Interventional | 2005-09-30 | Withdrawn (stopped due to No funding and exclusion criteria were to stringent.) | ||
| Combining a Dopamine Agonist and Selective Serotonin Reuptake Inhibitor for Treatment of Depression: A Double-Blind, Randomized Study[NCT00086307] | Phase 2 | 39 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Montgomery Asberg Depression Rating Scale (MADRS) is a 10 item scale for assessing the severity of depression. Items are rated on a scale of 0 to 6, so the maximum score is 60 and the minimum is 0, where 60 is the most severe depression. Scores of 18 or greater are generally considered to indicate a moderate level of depression. (NCT00086307)
Timeframe: Weekly
| Intervention | Score on a scale (Least Squares Mean) |
|---|---|
| Pramipexole | 22.629 |
| Escitalopram | 26.102 |
| Escitalopram and Pramipexole | 29.455 |
2 reviews available for amantadine and Chorea Disorders
| Article | Year |
|---|---|
[Chorea due to chronic subdural hematoma].
Topics: Aged, 80 and over; Amantadine; Chorea; Female; Hematoma, Subdural, Chronic; Humans; Magnetic Resonan | 2018 |
A systematic review of the treatment studies in Huntington's disease since 1990.
Topics: Amantadine; Antipsychotic Agents; Chorea; Depression; Humans; Huntington Disease; Neuroprotective Ag | 2007 |
4 trials available for amantadine and Chorea Disorders
| Article | Year |
|---|---|
Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine.
Topics: Adult; Aged; Amantadine; Chorea; Cognition; Cross-Over Studies; Dopamine Agents; Double-Blind Method | 2002 |
A randomized trial of amantadine in Huntington disease.
Topics: Amantadine; Chorea; Cross-Over Studies; Elbow; Female; Humans; Huntington Disease; Male; Mental Proc | 2003 |
Restatement and prospectives of ergot alkaloids in clinical neurology and psychiatry.
Topics: Aged; Amantadine; Basal Ganglia Diseases; Bromocriptine; Chorea; Clinical Trials as Topic; Depressio | 1978 |
Combined treatment of parkinsonism with L-dopa and amantadine.
Topics: Aged; Amantadine; Chorea; Clinical Trials as Topic; Dihydroxyphenylalanine; Female; Humans; Hypotens | 1970 |
15 other studies available for amantadine and Chorea Disorders
| Article | Year |
|---|---|
Anti-CV2/CRMP5 Paraneoplastic Chorea Effectively Managed with Intravenous Amantadine.
Topics: Administration, Intravenous; Amantadine; Autoantibodies; Carrier Proteins; Chorea; Dopamine Agents; | 2019 |
Paraneoplastic Chorea Managed with Intravenous Amantadine.
Topics: Amantadine; Chorea; Humans; Huntington Disease | 2019 |
Author Response to Letter to the Editor.
Topics: Amantadine; Chorea; Humans | 2019 |
A patient with 41 CAG repeats in SCA17 presenting with parkinsonism and chorea.
Topics: Amantadine; Antiparkinson Agents; Benzothiazoles; Brain; Chorea; Humans; Levodopa; Male; Middle Aged | 2016 |
Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology.
Topics: Adult; Amantadine; Anticonvulsants; Chorea; Evidence-Based Medicine; Humans; Huntington Disease; Ril | 2012 |
Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations.
Topics: Amantadine; Antiparkinson Agents; Child; Chorea; Dopamine Agents; Dyskinesia, Drug-Induced; GTP Cycl | 2004 |
Survival after treatment of rabies with induction of coma.
Topics: Adolescent; Amantadine; Anesthetics; Animals; Antiviral Agents; Athetosis; Benzodiazepines; Bites an | 2005 |
[A case of multiple cerebral infarctions associated with hemichorea induced by amantadine hydrochloride].
Topics: Aged; Aged, 80 and over; Amantadine; Cerebral Infarction; Chorea; Female; Humans; Tomography, Emissi | 1994 |
Letter: Amantadine in chorea.
Topics: Aged; Amantadine; Chorea; Drug Evaluation; Homovanillic Acid; Humans; Huntington Disease; Hydroxyind | 1975 |
Urinary monoamine metabolite excretion in disorders of movement. Effects of amantadine and levodopa.
Topics: Amantadine; Chorea; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Methylhistamines; | 1977 |
[Experiences with memantine in the treatment of severe spastic and extrapyramidal movement disorders in combination with stereotaxic surgery].
Topics: Adolescent; Adult; Aged; Amantadine; Athetosis; Basal Ganglia Diseases; Cerebral Palsy; Child; Chore | 1985 |
[Recent therapeutic conquests in extrapyramidal syndromes].
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Amantadine; Athetosis; Brain Diseases; Central | 1970 |
[Changes in the electroencephalogram during treatment with amantadine].
Topics: Amantadine; Brain; Chorea; Electroencephalography; Extrapyramidal Tracts; Humans; Movement Disorders | 1971 |
[On the therapeutic use of amantadine hydrochloride in non-parkinsonian hyperkinetic syndromes].
Topics: Adult; Amantadine; Athetosis; Brain Diseases; Brain Injuries; Cerebrovascular Disorders; Child; Chor | 1971 |
[Clinical and electroencephalographic observations on the action of amantadine in the dystonic-athetosic disorders of infentile cerebral paralysis].
Topics: Adolescent; Amantadine; Athetosis; Brain; Cerebral Palsy; Child; Child, Preschool; Chorea; Electroen | 1971 |